The FDA has approved an amino acid positron emission tomography drug for brain cancer imaging.
The drug — called Pixclara — differentiates recurrent or progressive glioma from treatment-related tissue changes, according to a Sept. 14 news release from the drugmaker, Telix.
Pixclara is approved for use in adults and pediatric patients 1 month and older, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
